Zacks Investment Research on MSN12h
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...
CSRWire19h
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research on MSN21h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
Winners and wishers: 8 potential Bay Area drug approvals coming this year
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Gilead, Regeneron have most theoretical PDUFA date risk, says BofA
With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...